Sham Mailankody, MBBS
Enriched profileClinical Director, Cellular Therapy Service and Research Director, Myeloma Service · Memorial Sloan Kettering Cancer Center
Sham Mailankody is Clinical Director, Cellular Therapy Service and Research Director, Myeloma Service at Memorial Sloan Kettering Cancer Center. OpenAlex indexes 483 publications with 8,984 citations (h-index 49); ClinicalTrials.gov lists 7 registered studies with this person as an investigator.
Data verified 17 Oct 2026
Overview
Updated 18 Oct 2026
Sham Mailankody, MBBS, is Clinical Director, Cellular Therapy Service and Research Director, Myeloma Service at Memorial Sloan Kettering Cancer Center. The public record shows 483 publications with 8,984 citations (h-index 49), centered on Multiple Myeloma Research and Treatments, CAR-T cell therapy research, Chronic Lymphocytic Leukemia Research. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 11 companies, 1 NIH-funded awards (2019–2020).
- Most recent indexed publication: 2026 · Nature reviews. Clinical oncology
- Top research focus: Multiple Myeloma Research and Treatments
- 7 registered trials on ClinicalTrials.gov
- Open Payments reporting from 11 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 37 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 138.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
- A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
Sponsor: Memorial Sloan Kettering Cancer Center
- CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Sponsor: Caribou Biosciences, Inc.
- A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
Sponsor: Memorial Sloan Kettering Cancer Center
Industry payments
Updated 18 Oct 2026
11 companies reported payments to CMS in program years 2022–2025. These are public disclosures, not judgments. The latest:
- Janssen Global Services, LLCProgram year20251 payment
- ABBVIE INC.Program year202510 payments
- E.R. Squibb & Sons, L.L.C.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
33%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor33%Acyclovir100%Part D≥48 patientsMetabolism & gastrointestinal
16.1%Proton pump inhibitor12.6%Omeprazole73%Pantoprazole Sodium27%Part D<11 patientsSerotonin-3 Receptor Antagonist3.4%Ondansetron Hcl100%Part D<11 patientsCancer & immunology
12.6%Thalidomide Analog12.6%Lenalidomide51%Revlimid33%Pomalyst16%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 18 Oct 2026
1 NIH research award on record, funded 2019–2020 per NIH RePORTER. The latest:
- Linking population-based data sources to examine health disparities in clinical trial participation and outcomes
Sloan-Kettering Inst Can Research
FY2020$195,315R21CA235154 - Linking population-based data sources to examine health disparities in clinical trial participation and outcomes
Sloan-Kettering Inst Can Research
FY2019$234,378R21CA235154
Congress activity
Updated 18 Oct 2026
130 congress contributions (2014–2026) across AACR, ASCO, ASH, ASTRO, ENDO per OpenAlex. The most recent:
- CAR T-cell detection and clonality assessment in immune effector cell–associated enterocolitis following ciltacabtagene autoleucel.
ASCO Annual Meeting
ASCO2026Co-author - Association of body mass index change and insulin resistance with survival during induction therapy in newly diagnosed multiple myeloma.
ASCO Annual Meeting
ASCO2025Co-author - Immune profiling to identify a functionally high-risk smoldering multiple myeloma patient population.
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- More options, more questions in the management of early relapsed and/or refractory multiple myeloma.
Nature reviews. Clinical oncology
Article2026 - Lenalidomide-Related Diarrhea in Patients with Multiple Myeloma Is Associated with Gut Microbiota Dysbiosis and Disruption of the Bile Acid Pool.
Clinical cancer research
Clinical Trial2026 - Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data.
Clinical pharmacology and therapeutics
Article2026 - Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry.
Blood cancer discovery
Article2026 - Lesion-level PET/CT analysis to identify predictors of progression after BCMA CAR T-cell therapy in multiple myeloma.
Blood cancer journal
Letter2026
Most-cited works
by citation count (OpenAlex)- 01
- 02The high price of anticancer drugs: origins, implications, barriers, solutionsReview444 citations2017
- 03GPRC5D-Targeted CAR T Cells for MyelomaArticle406 citations2022
- 04
- 05
Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/sham-mailankody-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- X / Twitter
twitter.com/MSKCancerCenter/status/1734297894000496789
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →twitter.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MBBS
K.S. Hegde Medical Academy
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Awards & honors
honors on the public record- Career Development Program award
The Leukemia & Lymphoma Society (now Blood Cancer United)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lls.org ↗
Secondary affiliations
appointments beyond the home institution- Member
Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mskcc.org ↗ - Member
Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mskcc.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center
Mark Kris, MD
Memorial Sloan Kettering Cancer Center
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
S Rajkumar, MD
Mayo Clinic
Meletios Dimopoulos, MD
National and Kapodistrian University of Athens